Archive by category | - Chris Dippel

Entrepreneurial life sciences companies have set their sights on overseas markets and have formed international partnerships to gain access to distribution channels and insight on product specifications, registration, and user preferences. I estimate that this “global health” market place is between $250-300 billion in annual sales, using a 2009 pharmaceutical sales forecast that put 14% of the total of $820 billion resulting from the emerging economies of China, Brazil, India, South Korea, Mexico, Turkey, and Russia (2009 Forecast), and so about 17% ($147 billion) occurred in the rest of world including those countries with few resources in health care. Applying the same ratio to a world diagnostics market of $44 billion, I add another $14 billion, giving a approximate non-US/EU/Japan global health pharma/diagnostics products market of $276 billion. Read more

Share/bookmark

Start up companies face a tough go- converting a new technology into saleable products on minimal funding- and those aiming at products for global health (or any health care products for sale outside the major market countries) have even a harder challenge by swimming against the conventional wisdom that a highly-priced, reimbursable product is the only way to profitability. For start-ups, time is money and the shorter time to a product prototype, the more likely is revenue and survival. To fund prototype development, most patch together funding from government (or very rarely, foundation) grants and private sources while trying to convince a major, established company that it wants access to the technology and/or the possibly-resulting products. Read more